By Ethan Covey
Data from the IMPAACT 2017/MOCHA study support the use of long-acting cabotegravir plus rilpivirine (CAB+RPV; Cabenuva, ViiV Healthcare) among virologically suppressed adolescents, as presented during the “ART nouveau” session at AIDS 2024, in Munich (abstract OAB2606LB).
The cohort from the phase 2/3 MOCHA (More Options for Children and Adolescents) trial performed by the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT 2017) included